CSL Biotherapies is a major supplier of vaccines and pharmaceuticals to Australia. Our strong commitment to research and development played a key role in the collaborative work that has made available the first vaccine against cervical cancer to the Australian community.
Key clinical studies central to the development of the vaccine were undertaken at the Royal Women's Hospital and we are delighted to support the Glitter Ball and to work with our partners to improve women’s health.